Craig R Cohen1, Michael R Wierzbicki1, Audrey L French1, Sheldon Morris1, Sara Newmann1, Hilary Reno1, Lauri Green1, Steve Miller1, Jonathan Powell1, Thomas Parks1, Anke Hemmerling1. 1. From the Departments of Obstetrics, Gynecology, and Reproductive Sciences (C.R.C., S.N., A.H.) and Laboratory Medicine (L.G., S. Miller), University of California, San Francisco, San Francisco, the Department of Family Medicine, University of California, San Diego, San Diego (S. Morris), and Osel, Mountain View (T.P.) - all in California; Emmes, Rockville, MD (M.R.W., J.P.); the Department of Medicine, Ruth M. Rothstein CORE Center and Stroger Hospital of Cook County Health, Rush University Medical Center, Chicago (A.L.F.); and the Division of Infectious Diseases, Department of Medicine, Washington University, St. Louis (H.R.).
Abstract
BACKGROUND:Bacterial vaginosis affects 15 to 50% of women of reproductive age, and recurrence is common after treatment with an antibiotic agent. The high incidence of recurrence suggests the need for new treatments to prevent recurrent bacterial vaginosis. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2b trial to evaluate the ability of Lactobacillus crispatus CTV-05 (Lactin-V) to prevent the recurrence of bacterial vaginosis. Women 18 to 45 years of age who had received a diagnosis of bacterial vaginosis and who had completed a course of vaginal metronidazole gel as part of the eligibility requirements were randomly assigned, in a 2:1 ratio, to receive vaginally administered Lactin-V or placebo for 11 weeks; follow-up occurred through week 24. The primary outcome was the percentage of women who had a recurrence of bacterial vaginosis by week 12. RESULTS: A total of 228 women underwent randomization: 152 to the Lactin-V group and 76 to theplacebo group; of these participants, 88% in the Lactin-V group and 84% in the placebo group could be evaluated for the primary outcome. In the intention-to-treat population, recurrence of bacterial vaginosis by week 12 occurred in 46 participants (30%) in the Lactin-V group and in 34 participants (45%) in the placebo group (risk ratio after multiple imputation for missing responses, 0.66; 95% confidence interval [CI], 0.44 to 0.87; P = 0.01). The risk ratio for recurrence by week 24 (also calculated with multiple imputation for missing responses) was 0.73 (95% CI, 0.54 to 0.92). At the 12-week visit, L. crispatus CTV-05 was detected in 79% of participants in the Lactin-V group. The percentage of participants who had at least one adverse event related to Lactin-V or placebo by week 24 did not differ significantly between the groups. The percentage of participants with local or systemic adverse events was similar in the two groups. CONCLUSIONS: The use of Lactin-V after treatment with vaginal metronidazole resulted in a significantly lower incidence of recurrence of bacterial vaginosis than placebo at 12 weeks. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT02766023.).
RCT Entities:
BACKGROUND:Bacterial vaginosis affects 15 to 50% of women of reproductive age, and recurrence is common after treatment with an antibiotic agent. The high incidence of recurrence suggests the need for new treatments to prevent recurrent bacterial vaginosis. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2b trial to evaluate the ability of Lactobacillus crispatus CTV-05 (Lactin-V) to prevent the recurrence of bacterial vaginosis. Women 18 to 45 years of age who had received a diagnosis of bacterial vaginosis and who had completed a course of vaginal metronidazole gel as part of the eligibility requirements were randomly assigned, in a 2:1 ratio, to receive vaginally administered Lactin-V or placebo for 11 weeks; follow-up occurred through week 24. The primary outcome was the percentage of women who had a recurrence of bacterial vaginosis by week 12. RESULTS: A total of 228 women underwent randomization: 152 to the Lactin-V group and 76 to the placebo group; of these participants, 88% in the Lactin-V group and 84% in the placebo group could be evaluated for the primary outcome. In the intention-to-treat population, recurrence of bacterial vaginosis by week 12 occurred in 46 participants (30%) in the Lactin-V group and in 34 participants (45%) in the placebo group (risk ratio after multiple imputation for missing responses, 0.66; 95% confidence interval [CI], 0.44 to 0.87; P = 0.01). The risk ratio for recurrence by week 24 (also calculated with multiple imputation for missing responses) was 0.73 (95% CI, 0.54 to 0.92). At the 12-week visit, L. crispatus CTV-05 was detected in 79% of participants in the Lactin-V group. The percentage of participants who had at least one adverse event related to Lactin-V or placebo by week 24 did not differ significantly between the groups. The percentage of participants with local or systemic adverse events was similar in the two groups. CONCLUSIONS: The use of Lactin-V after treatment with vaginal metronidazole resulted in a significantly lower incidence of recurrence of bacterial vaginosis than placebo at 12 weeks. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT02766023.).
Authors: Christina Gosmann; Melis N Anahtar; Scott A Handley; Mara Farcasanu; Galeb Abu-Ali; Brittany A Bowman; Nikita Padavattan; Chandni Desai; Lindsay Droit; Amber Moodley; Mary Dong; Yuezhou Chen; Nasreen Ismail; Thumbi Ndung'u; Musie S Ghebremichael; Duane R Wesemann; Caroline Mitchell; Krista L Dong; Curtis Huttenhower; Bruce D Walker; Herbert W Virgin; Douglas S Kwon Journal: Immunity Date: 2017-01-10 Impact factor: 31.745
Authors: H L Martin; B A Richardson; P M Nyange; L Lavreys; S L Hillier; B Chohan; K Mandaliya; J O Ndinya-Achola; J Bwayo; J Kreiss Journal: J Infect Dis Date: 1999-12 Impact factor: 5.226
Authors: Catriona S Bradshaw; Anna N Morton; Jane Hocking; Suzanne M Garland; Margaret B Morris; Lorna M Moss; Leonie B Horvath; Irene Kuzevska; Christopher K Fairley Journal: J Infect Dis Date: 2006-04-26 Impact factor: 5.226
Authors: Anke Hemmerling; William G Harrison; Joelle Morgan Brown; Barbara Moscicki; Maria Oziemkowska; Elizabeth A Bukusi; Craig R Cohen Journal: Sex Transm Dis Date: 2012-09 Impact factor: 2.830
Authors: Scott Sherrill-Mix; Kaleigh Connors; Grace M Aldrovandi; Jason M Brenchley; Charles Boucher; Frederic D Bushman; Ronald G Collman; Satya Dandekar; Nichole R Klatt; Laurel A Lagenaur; Roger Paredes; Gilda Tachedjian; Jim A Turpin; Alan L Landay; Mimi Ghosh Journal: AIDS Res Hum Retroviruses Date: 2020-09-07 Impact factor: 2.205
Authors: Scott Sherrill-Mix; Michelle Yang; Grace M Aldrovandi; Jason M Brenchley; Frederic D Bushman; Ronald G Collman; Satya Dandekar; Nichole R Klatt; Laurel A Lagenaur; Alan L Landay; Roger Paredes; Gilda Tachedjian; Jim A Turpin; Sergio Serrano-Villar; Catherine A Lozupone; Mimi Ghosh Journal: AIDS Res Hum Retroviruses Date: 2022-01-25 Impact factor: 2.205
Authors: Erica M Lokken; Clayton Jisuvei; James P Hughes; Kishor Mandaliya; Lisa E Manhart; Khamis Mwinyikai; Charles H Muller; Walter Jaoko; John Kinuthia; R Scott McClelland Journal: Fertil Steril Date: 2022-01-17 Impact factor: 7.329
Authors: Michelle L Wright; Jennifer M Fettweis; Lindon J Eaves; Judy L Silberg; Michael C Neale; Myrna G Serrano; Nicole R Jimenez; Elizabeth Prom-Wormley; Philippe H Girerd; Joseph F Borzelleca; Kimberly K Jefferson; Jerome F Strauss; Timothy P York; Gregory A Buck Journal: Commun Biol Date: 2021-08-05